Verona Pharma plc (VRNA) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2025-10-07

Verona Pharma plc (VRNA) — no SEC Form 4 insider filings recorded in the last 90 days. InsiderAlpha tracks every VRNA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Verona Pharma plc (VRNA)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001657312

Recent VRNA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-10-07	EBSWORTH DAVID R	Director	M — Option exercise	72.0K	—	—	SEC
2025-10-07	EBSWORTH DAVID R	Director	D — Derivative transaction	72.0K	—	—	SEC
2025-10-07	EBSWORTH DAVID R	Director	D — Derivative transaction	617.6K	—	—	SEC
2025-10-07	SHAH MAHENDRA	Director	D — Derivative transaction	93.5K	—	—	SEC
2025-10-07	SHAH MAHENDRA	Director	M — Option exercise	72.0K	—	—	SEC
2025-10-07	SHAH MAHENDRA	Director	D — Derivative transaction	72.0K	—	—	SEC
2025-10-07	Sinha Vikas	Director	D — Derivative transaction	94.1K	—	—	SEC
2025-10-07	Sinha Vikas	Director	M — Option exercise	72.0K	—	—	SEC
2025-10-07	Sinha Vikas	Director	D — Derivative transaction	72.0K	—	—	SEC
2025-10-07	Hahn Mark W	Chief Financial Officer	D — Derivative transaction	11.26M	—	—	SEC
2025-10-07	Hahn Mark W	Chief Financial Officer	M — Option exercise	3.29M	—	—	SEC
2025-10-07	Hahn Mark W	Chief Financial Officer	D — Derivative transaction	3.29M	—	—	SEC
2025-10-07	ZACCARDELLI DAVID	President and CEO	D — Derivative transaction	12.18M	—	—	SEC
2025-10-07	ZACCARDELLI DAVID	President and CEO	M — Option exercise	3.29M	—	—	SEC
2025-10-07	EBSWORTH DAVID R	Director	D — Derivative transaction	880.5K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Verona Pharma plc (VRNA). Updated in real time as new filings are submitted to the SEC.

Recent Insider Filings

2025-10-07 — SHAH MAHENDRA (Director)
2025-10-07 — Sinha Vikas (Director)
2025-10-07 — Hahn Mark W (Chief Financial Officer)
2025-10-07 — ZACCARDELLI DAVID (President and CEO)
2025-10-07 — EBSWORTH DAVID R (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in VRNA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

VRNA Insider Trading — FAQ

What is the latest insider trade for VRNA?: Verona Pharma plc (VRNA) had 0 insider filings in the last 90 days, with the most recent on 2025-10-07. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying VRNA stock?: 0 insider purchases of VRNA were filed in the last 90 days.
How many insiders are selling VRNA stock?: 0 insider sales of VRNA were filed in the last 90 days.
Where can I see VRNA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every VRNA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live VRNA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.